This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Nutt, D. Search for Related Content PubMed Articles by Nutt, D. Social Bookmarking                   What's this?

The anxiety factor in depression

Director, Psychopharmacology Unit, University of Bristol, Bristol, UK

Anxiety symptoms are commonly associated with depression, and contribute to a poorer patient prognosis. An increase in serotonergic function is implicated in the pathogenesis of anxiety and there is good evidence that the selective serotonin re-uptake inhibitors (SSRIs) may be useful in clinical management. Sertraline, a novel SSRI, has been shown to be effective in the treatment of anxiety symptoms in both pure and mixed anxiety disorders. Studies have also shown sertraline to be effective in obsessive-compulsive disorder. A recent study (Moon et al. , 1994) shows sertraline to have comparative therapeutic efficacy with that of clomipramine with respect to reduction of anxiety symptoms in depression. However, it also highlights important differences in side-effect profiles, with a high incidence of cardiovascular effects and subsequent dropouts reported in the clomipramine group. Limited comparative data with other SSRIs suggest there is no evidence of any aggravation of anxiety symptoms during treatment with sertraline, as has been reported with fluoxetine. Sertraline has been shown to have a normalising effect on sleep disturbance in depression without evidence of daytime sedation. Therefore, given the high prevalence of anxiety symptoms in depression, sertraline would be a useful therapeutic option in clinical management.

Key Words: sertraline • SSRI • anxiety • depression • insomnia • tricyclic antidepressant • review

Journal of Psychopharmacology, Vol. 9, No. 2 suppl, 185-189 (1995)
DOI: 10.1177/0269881195009002031


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				P. J. Goodnick and B. J. Goldstein Selective serotonin reuptake inhibitors in affective disorders -II. Efficacy and quality of life J Psychopharmacol, January 1, 1998; 12(4_suppl): S21 - S54. [Abstract] [PDF]